Biohaven Pharmaceutical Holding Stock Investor Sentiment

BHVN Stock  USD 40.69  0.50  1.21%   
About 57% of all Biohaven Pharmaceutical's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Biohaven Pharmaceutical Holding suggests that some traders are interested. Biohaven Pharmaceutical's investor sentiment overview provides quick insight into current market opportunities from investing in Biohaven Pharmaceutical Holding. The current market sentiment, together with Biohaven Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use Biohaven Pharmaceutical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

57

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Biohaven Pharmaceutical's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Biohaven Pharmaceutical Holding.
Biohaven Pharmaceutical stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Biohaven daily returns and investor perception about the current price of Biohaven Pharmaceutical Holding as well as its diversification or hedging effects on your existing portfolios.

Biohaven Historical Sentiment

Although Biohaven Pharmaceutical's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Biohaven, such as negative comments on social media and news outlets, may cause fear in the market and push Biohaven Pharmaceutical's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Biohaven.
  

Biohaven Pharmaceutical Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Biohaven Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biohaven Pharmaceutical Historical Investor Sentiment

Investor biases related to Biohaven Pharmaceutical's public news can be used to forecast risks associated with an investment in Biohaven. The trend in average sentiment can be used to explain how an investor holding Biohaven can time the market purely based on public headlines and social activities around Biohaven Pharmaceutical Holding. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biohaven Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biohaven Pharmaceutical and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Biohaven Pharmaceutical news discussions. The higher the estimate score, the more favorable the investor's outlook on Biohaven Pharmaceutical.

Biohaven Pharmaceutical Maximum Pain Price across 2024-05-17 Option Contracts

Biohaven Pharmaceutical's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Biohaven Pharmaceutical close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Biohaven Pharmaceutical's options.
few days ago at investorplace.com         
Shhh 3 Secret Biotech Stocks Flying Below Wall Streets Radar
sbwire news
six days ago at www.macroaxis.com         
Acquisition by Gregory Bailey of 16592 shares of Biohaven Pharmaceutical at 38.8 subject to Rule 16b...
Macroaxis News
over a week ago at simplywall.st         
Insider Spends US8.0m Buying More Shares In Biohaven
Simply Wall St News at Macroaxis
over a week ago at finance.yahoo.com         
Independent Director of Biohaven John Childs Buys 3.2 percent More Shares
Yahoo News
over a week ago at investing.com         
Biohaven director Bailey Gregory buys 999k in company shares
Investing News at Macroaxis
over a week ago at gurufocus.com         
Director Gregory Bailey Acquires 25,503 Shares of Biohaven Ltd
Gurufocus Stories at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Gregory Bailey of 25503 shares of Biohaven Pharmaceutical at .1785 subject to Rule 16...
Macroaxis News
over a week ago at investing.com         
Piper Sandler keeps Biohaven stock at Overweight after share offering
Investing News at Macroaxis
over a week ago at gurufocus.com         
Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Biohaven director John Childs acquires 7.99m in company stock
Investing News at Macroaxis
over a week ago at investing.com         
Biohaven director Bailey Gregory buys 2m in company shares
Investing News at Macroaxis
over a week ago at investing.com         
Biohaven CEO Vlad Coric buys 5 million in company shares
Investing News at Macroaxis
over two weeks ago at prnewswire.com         
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purcha...
prnewswire News
over two weeks ago at finance.yahoo.com         
Acquisition by Vlad Coric of 121951 shares of Biohaven Pharmaceutical at 41.0 subject to Rule 16b-3
Yahoo News
over two weeks ago at investing.com         
Biohaven prices public offering at 41, aims to raise 230 million for corporate expansion
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Biohaven Pharmaceutical that are available to investors today. That information is available publicly through Biohaven media outlets and privately through word of mouth or via Biohaven internal channels. However, regardless of the origin, that massive amount of Biohaven data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biohaven Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biohaven Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biohaven Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biohaven Pharmaceutical alpha.

Biohaven Pharmaceutical Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
02/29/2024
2
Acquisition by Vlad Coric of 231 shares of Biohaven Pharmaceutical subject to Rule 16b-3
04/05/2024
3
Biohaven retains stock target despite trial delay
04/15/2024
4
Biohaven launches 200 million public share offering
04/17/2024
5
Biohaven drops 4, prices 230M share offering
04/18/2024
6
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
04/22/2024
7
Biohaven director Bailey Gregory buys 2m in company shares
04/23/2024
8
Acquisition by Gregory Bailey of 25503 shares of Biohaven Pharmaceutical at .1785 subject to Rule 16b-3
04/24/2024
9
Independent Director of Biohaven John Childs Buys 3.2 percent More Shares
04/26/2024
10
Acquisition by Gregory Bailey of 16592 shares of Biohaven Pharmaceutical at 38.8 subject to Rule 16b-3
04/30/2024
11
Shhh 3 Secret Biotech Stocks Flying Below Wall Streets Radar
05/01/2024
When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:
Check out Biohaven Pharmaceutical Hype Analysis, Biohaven Pharmaceutical Correlation and Biohaven Pharmaceutical Performance.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Biohaven Stock analysis

When running Biohaven Pharmaceutical's price analysis, check to measure Biohaven Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biohaven Pharmaceutical is operating at the current time. Most of Biohaven Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biohaven Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biohaven Pharmaceutical's price. Additionally, you may evaluate how the addition of Biohaven Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Biohaven Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.73)
Return On Assets
(0.46)
Return On Equity
(0.84)
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.